23 May 2025 in Annals of the Rheumatic Diseases
Interleukin (IL)-17A is a key driver of spondyloarthritis (SpA) joint pathology. We aimed to identify its cellular source in synovial tissue from patients with 2 forms of SpA, namely axial SpA (AxSpA) and psoriatic arthritis (PsA). Synovial tissue from patients with SpA was profiled using single-cell RNA sequencing (scRNA-seq; AxSpA, n = 5; PsA, n = 6) or spatial RNA profiling (PsA, n = 4). CellPhoneDB was used to infer cell-cell communication. Tissue-resident memory Th17 (TRM17)-like cells were generated in vitro using blood memory CD4+ T cells from SpA patients. An epigenetic inhibitor library, siRNA, and clustered regularly interspaced short palindromic repeats (CRISPR) were used to identify epigenetic regulator(s) for TRM17. scRNA-seq showed that CD4+CXCR6+ TRM17 cells are the predominant spontaneous IL17A producers in SpA synovium. Cell-cell communication and single-cell spatial analysis support the interaction between TRM17 and CLEC10A+ dendritic cells, which were activated in SpA. Both sublining and lining fibroblasts in SpA synovium showed evidence of interleukin (IL)-17A activation. In vitro-generated CD4+ TRM17-like cells phenocopied joint tissue TRM17, producing IL-17A/F upon T cell-receptor (TCR) stimulation, which was further enhanced by cytokines. Perturbation of BRD1 inhibited the generation of TRM17-like cells. CD4+ TRM17 cells are the predominant source of IL-17A in SpA synovial tissue. TCR stimulation is essential for the secretion of IL-17A by CD4+TRM17-like cells. The epigenetic regulator bromodomain-containing protein 1 (BRD1) contributes to the generation of CD4+TRM17. Depleting CD4+TRM17 cells in SpA is thus a therapeutic strategy with potential to induce long-term remission.
18 October 2019 in Journal of Agricultural and Food Chemistry
26 October 2026 in Annals of the Rheumatic Diseases
Tumour necrosis factor (TNF) and interleukin (IL)-17 are central drivers of axial spondyloarthritis (AxSpA). We previously identified activated CD4+ tissue-resident memory Th17 cells as the principal source of IL-17A/F in AxSpA synovium. We sought to define the cellular source of TNF and mechanisms driving the CCL20+ myeloid phenotype in joint and blood. Single-cell RNA sequencing (scRNA-seq) of synovial tissue from 5 patients with AxSpA was combined with immunofluorescence, synovial-fluid scRNA-seq, and flow cytometry, as well as comparisons with rheumatoid arthritis datasets. Monocyte-derived macrophages from healthy controls (HCs) and patients with AxSpA were cocultured with activated autologous CD4+ T cells, with blocking and cytokine experiments defining mechanisms of CCL20+ induction. Circulating monocytes were assessed by scRNA-seq and functional assays. CCL20+ macrophages were the predominant source of TNF in AxSpA synovium, with TNF protein confirmed in tissue and synovial fluid. Activated CD4+ T cells induced the CCL20+ phenotype through CD40L-CD40 signalling and an IL-1β/TNF-α autocrine circuit in HC-derived and AxSpA-derived cells. Baseline AxSpA monocytes showed a higher CCL20+ signature than HC monocytes, but this difference largely disappeared after T-cell-mediated induction. Under stimulation, AxSpA monocytes also produced more TNF, IL-6, IL-1β, and IL-23 than HC monocytes, a difference attenuated following IL-1/TNF priming. CCL20+ macrophages are a major CD40L- and IL-1β/TNF-α-driven source of TNF in AxSpA synovium. AxSpA circulating monocytes exhibit heightened basal CCL20+ signatures and inflammatory responsiveness that converge towards HC responses after inflammatory priming, supporting circulating CCL20+ monocytes as a marker of IL-1β/TNF-α-driven myeloid inflammation.
15 October 2024 in bioRxiv
Objectives: Interleukin (IL)-17A is a key driver of Spondyloarthritis (SpA) joint pathology. We aimed to identify its cellular source in synovial tissue from patients with two forms of SpA namely Axial SpA (AxSpA) and Psoriatic arthritis (PsA). Methods: Synovial tissue from patients with SpA was profiled using single-cell RNA sequencing (scRNA-seq: AxSpA, n=5 and PsA, n=6) or spatial RNA profiling (PsA, n=4). CellPhoneDB was used to infer cell–cell communication. Tissue resident memory Th17 (TRM17)-like cells were generated in vitro using blood memory CD4+ T cells from SpA patients. An epigenetic inhibitor library, siRNA and clustered regularly interspaced short palindromic repeats (CRISPR) were used to identify epigenetic regulator(s) for TRM17. Results: scRNA-seq showed that CD4+CXCR6+ TRM17 cells are the predominant spontaneous IL17A producers in SpA synovium. Cell-cell communication and single-cell spatial analysis support the interaction between TRM17 and CLEC10A+ dendritic cells, which were activated in SpA. Both sublining and lining fibroblasts in SpA synovium showed evidence of IL-17A activation. In vitro-generated CD4+ TRM17-like cells phenocopied joint tissue TRM17, producing IL-17A/F upon T cell receptor (TCR) stimulation, which was further enhanced by cytokines. Perturbation of BRD1 inhibited the generation of TRM17-like cells. Conclusions: CD4+ TRM17 cells are the predominant source of IL-17A in SpA synovial tissue. TCR stimulation is essential for the secretion of IL-17A by CD4+TRM17-like cells. The epigenetic regulator BRD1 contributes to the generation of CD4+TRM17. Depleting CD4+TRM17 cells in SpA is thus a therapeutic strategy with potential to induce long-term remission. Key messages: What is already known on this topic: Interleukin (IL)-17A plays a key role in the immunopathogenesis of Spondyloarthritis (SpA), but its cellular source in joint tissue has not been determined previously. The induction and accumulation of CD4+ tissue resident memory Th17 (TRM17) cells following the clearance of pathogens has been described in skin, lung and kidney. Whether CD4+ TRM17 cells also accumulate in the joint and contribute to the pathology of SpA is not clear. What this study adds: CD4+ TRM17 cells are present in SpA synovial tissue and are the predominant source of IL17A CD4+ TRM17 cells in SpA joints express IL17A without any in vitro exogenous stimulation T cell receptor (TCR) rather than cytokine stimulation is essential for IL-17A production by CD4+ TRM17-like cells The epigenetic regulator BRD1 contributes to the generation of CD4+ TRM17-like cells. How this study might affect research, practice or policy: Our findings identify CD4+ TRM17 cells as the primary source of IL-17A in SpA synovium, a previously unrecognized role for these cells. Key questions remain: How do CD4+ TRM17 cells relate to IL-17A producers in synovial fluid? What mechanisms induce and maintain them in the joint? How do they interact with other cells to promote arthritis? These questions warrant further investigation. In addition, our data suggest that targeting CD4+ TRM17 cells, the “factory” of IL-17A in SpA synovial tissue, has the potential to induce long-term remission, encouraging future efforts to develop new therapies to deplete CD4+ TRM17 cells in SpA.